Case Report: clinical experience of bilateral giant pediatric Testicular adrenal rest tumors with 3 Beta-Hydroxysteroid Dehydrogenase-2 family history

Lingyun Yu, Pengyu Chen, Wenbin Zhu, Junjie Sun and Shoulin Li*

Abstract

Background: We reported a patient with Testicular adrenal rest tumors (TARTs) caused by congenital adrenal hyperplasia (CAH). TARTs occur frequently in CAH population with 21-hydroxylase deficiency (21-OHD). There are few reports of TARTs with 3β-hydroxysteroid dehydrogenase deficiency-2 (3β-2HSD). Furthermore, giant TARTs are rarely mentioned in reported cases involving affected siblings.

Case presentation: A 14-year-old male patient was admitted by congenital adrenal hyperplasia with progressively increasing bilateral testicular masses. The patient and his elder brother had been performed mutational and chromosome analysis and biopsy. Hormonal and anthropometric measurements were performed during endocrine treatments. We successfully performed surgery and excised two 83mm×46mm×44mm and 74mm×49mm×31mm tumors. Our pathology and immunochemistry tests have proven TARTs in patient. At first, both siblings received regular doses of hydrocortisone and fludrocortisone and tumor size regressed. During the one-year irregular intake due to Covid-19 pandemic, endocrine treatment became insensitive and tumor size slowly increased. The gene analysis reported two novel mutations C.776 C>T and C.674 T>A. The C.776 C>T is from father and has been reported. The C.674 T>A inherited from mother and cannot found in gene library and may related to TARTs.

Conclusions: This case illustrates inadequate hormone therapy could cause tumor enlargement. It is essential to seek for ultrasound examination once suspected scrotal mass occurred. It is necessary to adjust endocrine medicine or adopt surgery in refractory giant TARTs. And presence of tunica vaginalis cavity may indicate the severity of TARTs in surgery.

Keywords: TARTs, Testicular adrenal rest tumors, congenital adrenal hyperplasia, 3β-hydroxysteroid dehydrogenase deficiency-2, case report

Background

CAH is defined as autosomal recessive disease group mainly caused by enzymes defects that block adrenocorticosteroid synthesis-metabolism and cause disorders of sex development (DSD), which are common in female births and the reported incidence is about 1:15,000 [1]. CAH patients are always categorized as salt-wasting (SW), simple-virilizing (SV), non-classic (NC) types and it is essential for them, especially for SW type, to adopt life-long exogenous hormone therapy due to glucocorticoid (or with mineralocorticoid) deficiency and increased androgen secretion. Currently, several key synthesis enzyme genes were recognized as mutation
sites and CAH were classified as 21-OHD, 11β-hydroxylase deficiency (11β-OHD), 17α-hydroxylase deficiency (17α-OHD), 3β-2HSD and lipoid congenital adrenal hyperplasia (LCAH). The manifestations, mostly seen in 21-OHD, were suprarenal gland crisis and water-electrolyte imbalance. However, testicular adrenal rest tumors (TARTs), originated from testicular ectopic adrenal tissue, were occasionally reported in and correlated with lower fertility and infertility in male CAH group. In general, TARTs were always mentioned in 21-OHD and 11β-OHD. We reported one child with TARTs led by 3β-2HSD with family medical history after failure of endocrinology treatment and has accepted surgery in our hospital.

**Case presentation**

A 14-year-old boy was admitted for bilateral scrotal masses for 11 years in our outpatient department. According to the previous documents provided by his family, his parents were normal but his elder brother showed same scrotal masses. When they were 3 years old, the elder brother, who is 10 years older than the younger, accepted serious hypospadias repair surgery in 1999 while the younger in 2009 at Wuhan Children’s Hospital. In the short postoperative period, this younger child’s skin color became tanned and the color deepen. Although parents noticed that his testicles were slightly larger than peers in progressive pigmented stage, occasionally even with orchialgia, same to childhood of his elder brother, they still ignore it and did not take him to medical treatment until oversize bilateral lumps 5 years later. Thus his parents sent them to Tongji Hosiptal affiliated to Middle China University in Wuhan, and both were diagnosed as TARTs with 3β-2HSD by routine hormone examination (see in Fig. 1) and recommended gene analysis (see in Supplementary Fig. 1). In addition, tumor tissue biopsy approved by custodians also supported TARTs diagnosis. The markedly elevated

![Graph](image-url)  
*Fig. 1* We drew line graph (see in Fig. 1) to illustrate TARTs changes by incorporating various hormones. It is noteworthy, described by parents, that both of siblings showed hypospadias after birth and the whole body skin became dark in 3 years old.
androgen, ACTH and 17-OHP levels and actual bone age (15-year-old) indicated only hydrocortisone (HC) supplementary therapy feasible when they refused surgical excision. In long-term follow-up, HC dosage (15 mg/m²·d) was gradually adjusted to 23 mg/m²·d, which was proven effective by diminished tumor size. While two siblings often forgot to take medicine on time for one year and did not seek for regular examination due to COVID-19 epidemic in Wuhan. The bilateral TARTs size became slightly larger than pre-treatment and seemed insensitive to HC.

In the second admission to Shenzhen Children’s Hospital, we conducted sonography and computed tomography (CT) (show in Fig. 2). The physical examinations details included: Height 145.4 cm (-3.4 SD), Sitting Height 84.6 cm, Weight 55.7 kg. Pigmented Skin (see Supplementary Fig. 2). Tanner staging: breast B1, armpit hair A2, pubis PH5, penis 6 cm * 2.7 cm.

With slowly increased height about 1.2 cm since first admission 5 years ago, we replaced HC with dexamethasone (DXMS) to control the disease. The CT image suggested that testis tumor nearly replaced normal testicles tissue and hyperplasia in bilateral adrenal cortex. After multi-disciplinary discussion, the tumor was proposed to excise to avoid growing up and his parents accepted our advice.

After the incision into tunica vaginalis in each side, there is an obvious characteristic that cavity of tunica vaginalis disappeared, we can noticed two hard giant tumors (see Fig. 3) with several sporadic bean-like tubercles and cannot clearly distinguished structure of epididymis and testis. Finally, we stripped the tumor and suture incision by rolling residual testicular tissue and tunicae vaginalis. The tumors were demonstrated TARTs by pathology results (see in Supplementary Fig. 3 and Table 1) with no existence of Reinke crystals.

In the postoperative week, bilateral scrotum skin folds gradually resumed with subsidence of scrotum swelling and bilateral size obviously decreased comparing with primary manifestation.

During the third admission to Shenzhen Children’s Hospital in 2021 July, physical examinations included: Height 146.2 cm (-3 SD), Sitting Height 85.3 cm, Weight 64.5 kg, Pigmented Skin color improved. Tanner staging: breast B1, armpit hair A2, pubis hair PH5, penis 1 cm * 3.5 cm. The surgery incision recovered well and bilateral testis ultrasound show Left volume was 11.59 ml and Right was 10.79 ml. Adrenal hormone profile shows ACTH 4.090 pg/ml, testosterone 7.54 nmol/L, 17-OHP 0.47 nmol/L, serum cortisol is 0.000 ug/dl and follow-up is necessary for long-term prognosis.
Discussion and conclusions

3β-2HSD is a rare type of congenital adrenocortical hyperplasia, accounting for about 5% of CAH. In 3β-2HSD patients, SW type is usually confirmed in the neonatal period whereas the non-SW type before puberty[2]. 3β-HSD deficiency is caused by the deficiency of 3β-HSD2 and peripheral 3β-HSD1 is normal. During the fetal period, the activity of 3β-HSD2 remain high level to promote external genitalia development before 12 weeks in pregnancy[3]. Therefore, the lack of 3β-HSD2, in early stage of fetus, can damage the biosynthesis of testosterone at testis, resulting in incomplete masculinization, even complete feminization of external genitals. However, peripheral 3β-HSD1 activity peaked after the development of external genitalia (that is, the middle or later stage of pregnancy) and fail to develop normal male external genitalia, though 3β-HSD1 can mediate the conversion of excessive dehydroepiandrosterone to testosterone. For female group, lack of testosterone in early pregnancy leads to Wolffian duct degeneration and Müllerian duct evolve to fallopian tube and uterus. Be contrary to middle or later stage in male pregnancy, testosterone will increase androgen level, through mediation to dehydroepiandrosterone by peripheral 3β-HSD1, and impose mild masculinization on female external genitalia, like clitoris enlargement and/or without labial fusion.

The TARTs was firstly described by Wilkins in 1940[4], and the prevalence was 25% in childhood[5]. Non-typical sites like pelvis, retroperitoneum, kidney, spinal cord or Non-CAH diseases have been proven existence of adrenal rest tumors other than testis and CAH[5, 6]. At present, the etiology of TARTs was considered that chronic adrenocorticotropin hormone (ACTH) stimulates aberrant adrenocortical cells in testicular parenchyma. Most over 2 cm TARTs were detected by palpation while less 2 cm tumors were found in ultrasound and some TARTs regressed in the first year of life[6, 7]. In fact, most TARTs location is in the middle site of testis[7, 8] that is undetectable in physical examination and that is why we recommend ultrasound as the first means to screen testis tumor. Most TARTs are hypoechoic and bilateral while vascularity remains controversial for lack of objective values, machine settings difference and subjective judgment[9, 10]. In Magnetic Resonance Imaging (MRI), TARTs characterized with hypointensity on T2-W images, and hyperintensity or iso-intensity on T1-W images and lesion margins were clearly defined[5]. Owing to overlapping image results in Leydig tumors, clinical information and laboratory testing should be combined correct diagnosis. In fact, Miroslav Dumic[11] found that TARTs patients have been in stage 3 or 4 which should have accepted the early ultrasound examination. Since long-term over-exposure to ACTH will promote tumor growth in stage 2 and proceed into next stage, which is expected that tumor growth will restart after decreasing the dose of glucocorticoids in stage 3[12]. The RECIST (Response Evaluation Criteria in Solid Tumors) has proven previous tumor treatment ineffective in this child[13]. Therefore we excavted the surgery for this patient.

The TARTs origin recently was considered that it was related to a more pluripotent steroidogenic cell type that is already present in utero, probably originating from the adrenogonadal primordium or from the urogenital...
ridge [5, 12]. In addition, the excessive growth of tumor was hypothesized that may related to the ACTH/ Angiotensin II (Ang II) [14] or luteinizing hormone (LH) [12]. GATA transcription factor may also promote TARTs evolution [15]. While an inadequate hormonal control can led to a 16 times greater chance of 21-OHD CAH patient to present with TARTs and hormonal treatment reduction may induce renewed growth [5]. Hormonal control was defined as inadequate when 50% or more of serum androstenedione results were above reference values, and 50% or more of serum 17-OH-concentrations were over 5 times the upper limit of reference values per age [16]. Thus the 3β-2HSD CAH patient should follow regular and low-risk hormonal therapy dosage, and overdose may cause tumor evolution and lower expected height [7, 16]. However, there is no enough data to estimate rational choice of hormone like dexamethasone. It is necessary for attempt of increasing Gamma Knife Surgery (GKS) doses to avoid excess endocrine treatment and estimate if the growth of the tumor is reversible in the I to III phase [17, 18]. It is essential that we should calculate the prevalence of TARTs without medicine intervention, especially failure of hormonal treatment.

Although Claahsen-van [17] has described the TARTs evolution, Stage 5 characteristics of the classification is not clear. In this case, the mentioned diappearing cavity of tunica vaginalis, which may caused by compression of tumor growth, can be used to explicitly describe TARTs satges for determining surgical treatment. Tunica vaginalis [19] is a mesothelium-lined sac that results from closure of the superior portion of the processus vaginalis, which is thought to be mediated by androgen, smooth muscle cell [20] and autonomic nervous system [21]. In spite of unclear mechanism preventing tunica vaginalis obliteration, Hutson [22] found tunica vaginalis cavity volume shrinks with the age in postmortem adult groups. It is necessary to explore the potential impact on tunica vaginalis in endocrine diseases population accompanied by ubiquitous hormone disorder.

Besides, fertility loss is deemed as the complication in TARTs cases and always related mechanical obstruction and toxic effect of local adrenal steroids or metabolites derived from adrenal rest tumors [23]. In spite of infertility, some effective treatments have been proposed like follicle-stimulating hormone (FSH)/LH induction or mitotane therapy [24]. In most azoospermia or oligozoospermia patients affected by CAH, there are several reversible fertility TARTs cases [25], which could provide some guidance for 3β-2HSD population.

The cavity of tunica vaginalis may indicate the severity of TARTs. It is essential to seek for ultrasound examination once suspected scrotal mass occurred. It is necessary to adjust endocrine medicine or adopt surgery when regular and adequate hormone therapy was ineffective or refractory gaint TARTs emerged. Semen analysis were considered an assistant means to preserve fertility in male CAH patients.

Abbreviations
TARTs: Testicular adrenal rest tumors; CAH: congenital adrenal hyperplasia; 3β-2HSD: 3β-hydroxysteroid dehydrogenase deficiency-2; DSD: disorders of sex development; 3W: salt-wasting; 5W: simple-wirillating; NC: non-classic; 21-OHD: 21-hydroxylase deficiency; 11β-OHD: 11β-hydroxylase deficiency; 17α-OHD: 17α-hydroxylase deficiency; 3β-2HSD: 3β-hydroxysteroid dehydrogenase type II; LAH: lipoïd congenital adrenal hyperplasia 12; HC: hydrocortisone; CT: computed tomography; MRI: Magnetic Resonance Imaging; ACTH: adrenocorticotropic hormone; DXM: dexamethasone; SD: Standard Deviation; RECIST: Response Evaluation Criteria in Solid Tumors; Ang II: Angiotensin II; FSH: follicle-stimulating hormone; LH: luteinizing hormone; GKS: Gamma Knife Surgery

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1186/s12887-021-02883-x.

Acknowledgments
The case involving patient’s privacies are concealed in this paper. We have been authorized by patient’s parent for exclusively using medical information relative to this case and approved by the Shenzhen Pediatric Hospital of China Medical University. Our hospital pathologist Jianming Song, also offers support in interdepartmental coordination, Shenzhen’s Sanming Project. The patient’s parent has signed the informed consent document provided by us. The informed document is confined to the publication of this case report and any accompanying images.

Authors’ contributions
LY and PC acquired the data and responsible for analyzing and interpreting them. WZ is responsible for drawing hormone level graph and pedigree. JS is the surgery operator and record surgery process. LY prepared the manuscript. JS and SL revised the manuscript and provide instruction to this report. All authors have read and approved the manuscript.

Funding
LY, PC and SL was in part supported by Shenzhen health system research project (No:SZXJ2018045) and Sanming Project of Medicine in Shenzhen (No:SZSM20162013).

Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate
Informed consent was obtained from the patient's parents for the publication of this case report. The Shenzhen Children’s Hospital Ethics Committee has approved our application for publication.

Consent for publication
Written informed consent was obtained from the parents/guardians of the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 2 June 2021 Accepted: 8 September 2021
Published online: 15 September 2021

References

1. White P, Speiser P. Congenital adrenal hyperplasia due to 21-hydroxylation deficiency. Endocr Rev. 2000;21(3):245–91. doi:https://doi.org/10.1210/edrv.21.3.0398. PubMed PMID: 10857554.

2. Johannsen T, Mallard D, Dege-Petersen H, Müller J, Main K, Morel Y, et al. Delayed diagnosis of congenital adrenal hyperplasia with salt wasting due to type 1 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab. 2005;90(4):2076–80. doi:https://doi.org/10.1210/jc.2004-1374. PubMed PMID: 15671104.

3. Levy-Shaya V, Pinhas-Hamod O. High 17-hydroxyprogesterone level in newborn screening test for congenital adrenal hyperplasia. BMJ case reports. (2010) 2016. doi: https://doi.org/10.1136/bcr-2015-213939. PubMed PMID: 26912766.

4. Wilkins WF, Howard JE. Macrogenitosomia precox associated with hyperplasia of the androgenic tissue of the adrenal and death from corticoadrenal insufficiency. Endocrinology (1940) Volume 26(issue 3):pages 385 – 95. doi: https://doi.org/10.1210/endo-26-3-385.

5. Engels M, Span P, van Herwaarden A, Sweep F, Claahsen-van der Grinten HL. Prevalence and ultrasound patterns of testicular adrenal rest tumors in patients with congenital adrenal hyperplasia—cross-sectional study of 51 Croatian male patients. Eur J Paediatrics. 2017;176(10):1393–404. doi: https://doi.org/10.1007/s00431-017-3008-7. PubMed PMID: 28879515.

6. Smeets E, Span P, van Herwaarden A, Wevers R, Hermus A, Sweep F, et al. Molecular characterisation of testicular adrenal rest tumours in congenital adrenal hyperplasia: lesions with both adrenocortical and Leydig cell features. J Clin Endocrinol Metab. 2015;100(3):E524–30. doi:https://doi.org/10.1210/jc.2014-20436. PubMed PMID: 25485724.

7. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford England: 1990) 2009;45(2):228–47. doi:https://doi.org/10.1016/j.ejca.2008.10.006. PubMed PMID: 19097774.

8. Lottrup G, Nielsen JE, Skakkebaek NE, Juul A, Rajpert-De Meyts E. Abundance of DVL1, differential expression of CYP11B1, CYP21A2 and MC2R, and lack of INSL3 distinguish testicular adrenal rest tumours from Leydig cell tumours. European journal of endocrinology. 2015;172(4):491–9. doi:https://doi.org/10.1530/eje-14-0810. PubMed PMID: 25609776. Epub 2015/01/23.

9. Engel M, Span P, Mitchell R, Heuvel J, Marinjissen-van Zanten M, van Herwaarden A, et al. GATA transcription factors in testicular adrenal rest tumours. Endocrine connections. 2017;6(8):866–8.75. doi:https://doi.org/10.1530/ec-17-0215. PubMed PMID: 26938332.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.